TriAL21 study is an interventional, open, one arm, prospective, national and single center study. A total of 200 patients with Down syndrome, aged 35 years and over, without diagnosis of Alzheimer's disease will be enrolled into the study. Participating centre is Institut Jérôme Lejeune; outpatient's clinic dedicated to treating patients with cognitive deficiencies of genetic origin including patients with Down syndrome.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age of onset of Alzheimer's disease
Timeframe: 2 years
Gender that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Level of intellectual diasability that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Family history of Alzheimer's disease that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Cardio-vascular risk factors that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Down syndrome comorbidies that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Genetic's factor other than APP that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Anne-Sophie REBILLAT, MD, PhD
Head trauma that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years
Age of menopause that could influence the age of onset of the disease as determined by medical record review
Timeframe: 2 years